Market Overview: The Pharmacovigilance drug safety software market was valued at USD 1506.26 Million in 2022, with a projected growth to reach USD 2544.36 Million by 2032 at a Compound Annual Growth Rate (CAGR) of 6% during the forecast period.
Pharmaceutical companies, contract research organizations (CROs), and regulatory bodies rely on pharmacovigilance drug safety software to monitor adverse drug reactions (ADRs) and ensure the safety and effectiveness of medications. The increasing prevalence of ADRs, driven by the use of drugs and clinical trials, has heightened the demand for pharmacovigilance drug safety software.
Stringent rules and guidelines set by global regulatory organizations, including the World Health Organization (WHO), the European Medicines Agency (EMA), and the United States Food and Drug Administration (FDA), now require pharmaceutical companies and CROs to adopt pharmacovigilance drug safety software for efficient ADR handling and reporting.
Get a sample copy of the Pharmacovigilance Drug Safety Software Market report: https://www.reportsanddata.com/download-free-sample/7283
Manufacturers are continuously developing technologically advanced software capable of managing, tracking, and analysing drug safety data to meet the growing demand for effective and affordable pharmacovigilance drug safety solutions. The utilization of cloud-based software and artificial intelligence (AI) further contributes to the growth of market revenue.
Various industries, such as pharmaceuticals, biotech, and medical devices, are witnessing an increased demand for pharmacovigilance drug safety software, driven by advancements in technology, including Predictive Analytics, signal identification, and risk management.
Type Outlook: The software for recording adverse events is a critical component of pharmacovigilance medication safety procedures. As the number of pharmaceuticals and patients increases, the importance of adverse event reporting software in gathering, monitoring, and analyzing patient and healthcare professional reports also grows.
The segment selling software for drug safety audits is expected to experience the fastest revenue growth during the forecast period. The increasing demand for precise and effective medication safety monitoring, the adoption of electronic health records (EHRs), and technological advancements are key factors driving this growth. Software for drug safety audits assists organizations in identifying safety concerns, ensuring regulatory compliance, and improving pharmacovigilance operations.
The signal detection software segment is also anticipated to expand significantly, with organizations using this software to proactively monitor drug safety by identifying potential risks based on adverse event report patterns and trends. The demand for signal detection software is expected to rise due to the expanding need for proactive drug safety monitoring and advancements in data analytics and machine learning.
The increased focus on patient safety and regulatory compliance is expected to drive the adoption of pharmacovigilance medication safety software across the globe. Governments worldwide are intensifying efforts to ensure the efficacy and safety of medications, leading to the implementation of stringent rules and regulations that necessitate the use of pharmacovigilance drug safety software by organizations to ensure patient safety.
End-Use Outlook: Pharmaceutical and biotechnology corporations are the primary consumers of pharmacovigilance drug safety software as they are responsible for developing and introducing new medications to the market. These organizations are mandated to conduct rigorous drug safety monitoring throughout the entire drug development process, from clinical trials to post-marketing surveillance. Pharmacovigilance drug safety software enables systematic and effective collection and analysis of adverse event data, helping these businesses identify potential safety issues.
Contract research organizations (CROs) widely use pharmacovigilance software for drug safety, providing support to pharmaceutical and biotechnology companies in clinical trials and drug development. CROs play a crucial role in ensuring legal and regulatory compliance, and the use of pharmacovigilance drug safety software reduces the risk of errors and delays in adverse event reporting and monitoring.
Academic and research institutes, regulatory bodies, and other healthcare organizations fall under the “others” sector. These organizations play a vital role in drug safety monitoring, and pharmacovigilance drug safety software facilitates the collection and processing of adverse event reports. Regulatory organizations, such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), require pharmaceutical companies to submit comprehensive safety information as part of the drug clearance process. The use of pharmacovigilance drug safety software enables these organizations to manage and analyze data more efficiently, ensuring the safety and efficacy of medications for patients.
The demand for new pharmaceuticals is expected to rise, leading to an increased complexity of drug safety laws and, consequently, a higher adoption of pharmacovigilance drug safety software. This software is crucial for pharmaceutical and biotechnology companies, CROs, and other healthcare organizations facing growing pressure to guarantee the safety and efficacy of medications.
Regional Outlook: North America is expected to dominate the global pharmacovigilance drug safety software market during the forecast period, driven by the presence of significant pharmaceutical companies such as Pfizer, Johnson & Johnson, and Merck & Co., Inc. The region’s demand for pharmacovigilance drug safety software is further fueled by the increasing trend of pharmaceutical corporations outsourcing pharmacovigilance work to contract research organizations (CROs).
The Asia Pacific region is anticipated to experience significant growth in the pharmacovigilance drug safety software market during the forecast period. Factors contributing to the market expansion in this region include the rise in clinical trials and the use of pharmacovigilance software by pharmaceutical firms to meet regulatory requirements. The vast population base in the region, along with the increasing incidence of adverse drug reactions (ADR), is expected to further drive market expansion.
The European market is also expected to witness growth in the pharmacovigilance drug safety software market, with factors such as the rising prevalence of chronic diseases and the need to monitor and prevent adverse drug reactions contributing to the expansion. The presence of significant pharmaceutical corporations in the UK and Germany positions these countries as key players in the European market.
Competitive Landscape: Key players in the pharmacovigilance drug safety software market include Oracle Corporation, ArisGlobal LLC, Anju Software Inc, Mediware Information Systems Inc, AB Cube, Extedo GMBH, Online Business Applications, Inc., United BioSource Corporation, DSG Inc, PVCON Inc, and Instem PLC.
Strategic Developments:
- In October 2021, Oracle Corporation announced the acquisition of Cognate Bioservices, a cell and gene therapy contract development and manufacturing organization (CDMO), aiming to enhance Oracle’s Pharmacovigilance Cloud platform.
- In September 2021, ArisGlobal LLC entered a strategic partnership with Korean clinical research organization (CRO) MediNet Co., Ltd. to expand its presence in the Asian market.
- In 2020, Anju Software, Inc. acquired Sylogent, a regulatory information management solutions provider, to enhance its pharmacovigilance software offerings.
- In 2020, DSG, Inc. acquired ClinSpark, a provider of clinical trial software solutions, to expand its pharmacovigilance software offerings.
- In 2020, United BioSource Corporation announced a strategic partnership with TriNetX to enhance its pharmacovigilance capabilities by integrating real-world data and analytics.
New Product Launches:
- In 2021, Oracle Corporation launched Oracle Safety One, a cloud-based pharmacovigilance solution.
- In 2020, ArisGlobal LLC launched LifeSphere Safety MultiVigilance 10.1, an advanced pharmacovigilance solution.
Explore Trending Reports:
Software Asset Management Market-https://www.globenewswire.com/news-release/2019/07/29/1892946/0/en/Software-Asset-Management-Market-To-Reach-USD-3-92-Billion-By-2026-Reports-And-Data.html
Smart Governments Market-https://www.globenewswire.com/news-release/2019/12/17/1961293/0/en/Smart-Governments-Market-To-Reach-USD-52-19-Billion-By-2026-Reports-And-Data.html
Procure To Pay Software Market-https://www.globenewswire.com/news-release/2019/09/05/1911800/0/en/Procure-To-Pay-Software-Market-To-Reach-USD-9-2-Billion-By-2026-Reports-And-Data.html
Request a customization of the report: https://www.reportsanddata.com/request-customization-form/7283
Thank you for reading our report. To know more about the customization or any query about the report contents, please connect with us and our team will ensure the report is tailored to meet your requirements.
About Reports and Data   Â
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web:Â www.reportsanddata.com
Direct Line:Â +1-212-710-1370
E-mail:Â sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @Â https://www.reportsanddata.com/report
Browse Latest Blogs: https://www.reportsanddata.com/blogs
Browse Latest Press Release: https://www.reportsanddata.com/press-release
